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Chloramphenicol (Chl) is an effective antimicrobial agent widely used in veterinary medicine and
commonly used in ﬁsh. Its use is restricted in the clinic because of adverse effects on the immune
system and oxidative stress in mammals. However, the effects of Chl treatment on invertebrates
remain unclear. Amphioxus, a basal chordate, is an ideal model to study the origin and evolution
of the vertebrate immune system as it has a primary vertebrate-like arachidonic acid (AA) metabolic
system. Here, we combined transcriptomic and lipidomic approaches to investigate the immune sys-
tem and observe the oxygenated metabolites of AA to address the antibiotic effects on amphioxus.
Tissue necrosis of the gill slits occurred in the Chl-treated amphioxus, but fewer epithelial cells were
lost when treated with both Chl and ampicillin (Amp). The immune related pathways were dysreg-
ulated in both of the antibiotic treatment groups. The Chl alone treatment resulted in immunosup-
pression with down-regulation of the innate immune genes. In contrast, the Chl + Amp treatment
resulted in immunostimulation to some extent, as shown by KEGG clustering. Furthermore, Chl
induced a 3-fold reduction in the level of the eicosanoids, while the Chl + Amp treatment resulted
in 1.7-fold increase of eicosanoid level. Thus in amphioxus, Amp might relieve the effects of the
Chl-induced immune suppression and increase the level of eicosanoids from AA. Finally, the oxy-
genated metabolites from AA might be crucial to evaluate the effects of Chl treatment in animals.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction However, Chl is restricted in the clinic and banned inChloramphenicol (Chl) is a highly effective antimicrobial agent
that has been used to treat typhoid fever, meningitis, and certain
infectionsof the central nervous systemsince1948 [1–3]. In the clin-
ical context, a combination of Chl and ampicillin (Amp) treatment is
used to treat severe purulent exacerbations of bronchitis and sys-
temic haemophilus inﬂuenza disease [4–9]. Chl + Amp treatment
is synergistic against gram-negative bacteria [10]. Furthermore,
typhoid fever patients treated with Chl + Amp have a shorter febrile
period compared to patients treated with Chl alone [11].food-producing animals [12–15] because of its adverse effects.
Chl treatment in mammals can induce complicated physiological
and pathological effects. The most prominent feature of the
adverse effects of Chl treatment is immune depression with irre-
versible aplastic anemia and gray baby syndrome [16–18]. Chl
can also induce abnormal T cell differentiation and the inhibition
of T cell apoptosis [19]. Chl-treated dogs show complex hemato-
logic changes, which includes polychromasia, anisocytosis, vacuo-
lation of lymphocytes, and basophilic granule formation in
neutrophils [20]. Chl treatment could also signiﬁcantly suppress
antigen-induced lymphocyte blastogenesis [21]. Another remark-
able feature associated with Chl treatment is the induction of
the oxidative stress response and an increase in reactive oxygen
species production [16–18].
Oxidative stress affects the oxidative metabolism of polyunsat-
urated fatty acids through enzymatic and free radical-mediated
reactions [22]. Oxygenated metabolites from arachidonic acid
616 D. Yuan et al. / FEBS Open Bio 5 (2015) 615–624(AA) are produced by the catalytic reaction of two principal
dioxygenase enzymes, namely cyclooxygenases (COX) and
lipoxygenases (LOX), as well as mono-oxygenases (CYP) of the
cytochrome P450 family. Eicosanoids from AA are a family of
bioactive lipids, which are associated with a wide variety of
physiological activities as well as pathological responses and often
exhibit potent immune properties in mammals [23,24]. Thus, we
hypothesize that the level of eicosanoids from AA may be crucial
to evaluate the homeostasis of animals and might reﬂect the
effects of Chl treatment on animals.
Chl is still widely used in veterinary medicine and commonly
used in ﬁsh because it is a highly effective and well-tolerated
broad-spectrum antibiotic [12,25]. However, the effects of Chl
treatment on invertebrates remain unclear. Amphioxus is an
example of a primitive chordate that has unique features, which
make it an ideal model for investigating the origin and evolution
of the vertebrate immune system [26,27]. Amphioxus has a
complex mucosal immune system, which is involved in host
defense after pathogen stimulation [28]. Furthermore, we previ-
ously identiﬁed an AA-metabolic system with COX, LOX, and CYP
pathways in amphioxus [29]. Thus, considering the complicated
consequences associated with Chl treatments in human and
animal models, a comprehensive investigation will serve as a
powerful approach to explore these complex effects in inverte-
brates. Thus, we combined transcriptomic and lipidomic
approaches with KEGG clustering to address the impact of antibi-
otics on amphioxus. Understanding these effects on amphioxus
will help to evaluate the efﬁciency of Chl usage in the aquatic
invertebrate species.
2. Materials and methods
2.1. Animals and sample acquisition
Adult Chinese amphioxus Branchiostoma belcheri were
obtained from the Beihai Bay, China. The location is 20010N,
107420 E. The experimental use of amphioxus has been approved
and supervised by the Animal Care and Ethics Committee (ACEC)
of the School of Life Sciences (SOLS) at Sun Yat-sen University
since 2010 (track: SYSU-SOLS-ACEC2010B0022). SOLS ACEC
ensures that animal experiments abide by local laws and the
International Guiding Principles for Biomedical Research Involving
Animals as issued by the Council for the International
Organizations of Medical Sciences.
Amphioxus were cultured in aerated seawater and fed microal-
gae daily for more than three months. They were sorted into two
antibiotic treatment groups, Chl, and Chl plus Amp. A third group
of amphioxus was cultured in fresh seawater as a control. For the
control amphioxus group, day 0 was used as the reference basis for
investigating the histological changes, lipid levels, and gene
expression in both of the antibiotic treatments groups. The
antibiotic-treated groups consisted of ﬁfteen amphioxus that were
cultured in 2 L of seawater with aeration and treated with either
62.5 mg/L Chl in seawater (Chl group) or 62.5 mg/L Chl plus
0.5 g/L Amp in seawater (Chl + Amp group). The dose of antibiotics
was based on previous reports on the effects of Chl treatment
[30–32]. The experimental ratio of Chl and Amp was based on
the clinical usage and the bactericidal activity with Chl + Amp
treatment [10,11,33]. For histological observation, the digestive
tract tissues of adult amphioxus were collected after 0, 2, 4, 6,
and 8 days of treatment. For transcriptomic and lipidomic analy-
ses, the pooled tissues samples were collected from the pharyngeal
gill slits to the intestine of the adult amphioxus digestive systems.
Six female and male adult amphioxus were used for each sample
in the histological, transcriptomic and lipidomic experiments,
respectively.2.2. Histological protocol
At 2, 4, 6, and 8 days, the adult amphioxus were killed and ﬁxed
in 4% paraformaldehyde in phosphate buffered saline (PBS) buffer
at 4 C for 12 h, dehydrated with graduated ethanol, and embedded
in parafﬁn. The parafﬁn blocks were cut into 5 lm sections, stained
with hematoxylin and eosin, and examined microscopically at
35- and 630 with oil immersion.
2.3. Transcriptomic analysis of amphioxus
We collected tissue of the amphioxus digestive system from the
pharyngeal gill slits to the intestine. Total RNA was extracted with
TRIZOL (Invitrogen), and the cDNA libraries were prepared using
the Truseq™ RNA Sample Preparation Kit (Illumina). The
antibiotic-free, Chl1d, Chl + Amp1d, Chl4d, and Chl + Amp4d
libraries were primer-end labeled with CGATGT, TGACCA,
ACAGTG, CGATGT, and TGACCA, respectively. For PCR efﬁciency,
the number of cycles was limited to 15 to reduce the effect of base
mutations, redundant fragments, and guanine and cytosine (GC)%
disparity. The PCR amplicon libraries were generated for each
sample and detected with an Agilent Bioanalyzer 2100 (Agilent),
quantiﬁed with a Qubit 1.0 spectroﬂuorometer (Invitrogen), and
pyrosequenced by Genome Analyzer IIx (Illumina). The transcrip-
tomic sequences have been deposited in the NCBI Short Read
Archive database (accession No. SRP035372).
2.4. Transcriptome data analysis
Extracted RNA fragments of 390 bp were subjected to
sequencing (Table S1). The transcriptomic data was analyzed
according to a previous report [29]. We identiﬁed 3530
differentially expressed genes (DEGs) (>1000 DEGs in each sample)
that were signiﬁcantly up- or down-regulated based on a t-test
(P < 0.05) and false discovery rate (FDR < 0.05) (Fig. 3A). A GO
function analysis (TermFinder: http://search.cpan.org/dist/
GO-TermFinder/) (corrected P < 0.05) [34] and KEGG pathway
analysis (DAVID: http://david.abcc.ncifcrf.gov/) (P < 0.05) of the
DEGs was conducted [35]. A comprehensive comparison of a select
set of KEGG pathways [36] in both of the antibiotics-treated
amphioxus groups, on the basis of the time-course of the propor-
tion of signiﬁcantly regulated genes, is shown in Tables 1 and S3.
The KEGG pathways were classiﬁed as the commonly and uniquely
regulated pathways.
2.5. Expression patterns detected by real-time PCR
Total RNA was extracted from the samples using TRIZOL
(Invitrogen) and treated with deoxyribonuclease (DNaseI).
Double-stranded cDNA was synthesized using reverse transcrip-
tion (TOYOBO) and quantiﬁed with the LightCycler 480 (Roche).
Eighty-one immune and oxygenated-metabolic candidate genes
were selected for qPCR to monitor their modulation of time in
response to Chl (0–8 days) and Chl + Amp (0–8 days) treatments
according to a previous report [28]. The values were considered
to be signiﬁcant at P < 0.05. Digital expression proﬁling with differ-
ent antibiotic treatments were roughly consistent with the qPCR
expression levels (Table S4), with a Pearson correlation coefﬁcient
of 0.82 and 0.80 on day 4 of Chl and Chl + Amp treatments, respec-
tively (P < 0.05).
2.6. Section in situ hybridization
Male and female adult B. belcheri were cut into 1-cm sections
and ﬁxed in 4% paraformaldehyde in PBS buffer at 4 C overnight,
dehydrated with graduated ethanol, and embedded in wax. The tis-
sue blocks were then cut into 8-mm sections. The 30 end fragments
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cloned into the T Easy Vector (Promega) (Supplementary
Table S1). DIG-labeled sense (synthesized by T7 RNA polymerase
for BbtCOX-c and BbtCOX-d) and antisense (synthesized by SP6
RNA polymerase for BbtCOX-c and BbtCOX-d) probes were gener-
ated at the 30 end sequences as a template with the DIG RNA
Labeling Kit (Roche). The secting procedure for in situ hybridization
was performed as previously described [29].2.7. Eicosanoid measurement in the amphioxus digestive tract
Amphioxus tissues were snap-frozen in liquid nitrogen and
stored at 80 C until lipid extraction. For extraction, the tissue
was pulverized and the frozen powder was immediately placed in
3 ml of ice-cold 100% ethanol and weighed. Ten microliter of the
antioxidant cocktail (0.2 mg/ml butylated hydroxytoluene,
0.2 mg/ml EDTA, 2 mg/ml triphenylphosphine, and 2 mg/ml indo-
methacin in a solution of 2:1:1 methanol:ethanol:H2O) was added
to each sample, and all of the tubes were incubated on ice at
20 C for 72 h. The samples were then centrifuged at 3500g for
30 min, and the ethanol supernatant was transferred to a new tube
and dried under nitrogen gas. The samples were reconstituted with
2 ml of 10% MeOH and supplemented with 50 ng of the following
deuterated eicosanoids (Cayman Chemical): (d4) 6-keto-
prostaglandin F1a (6k-PGF1a), (d4) thromboxane B2 (TXB2), (d4)
prostaglandin F2a (PGF2a), (d4) prostaglandin E2 (PGE2), (d4) pros-
taglandin D2 (PGD2), (d4) 15-deoxy-prostaglandin J2 (15d-PGJ2),
(d4) leukotriene B4 (LTB4), (d6) 20-hydroxyeicosatetraenoic acid
(20-HETE), (d8) 5-hydroxyeicosatetraenoic acid (5-HETE), (d8)
15-hydroxyeicosatetraenoic acid (15-HETE), (d11) 8,9-epoxyei-
cosatrienoic acid (8,9-EET), and (d11) 11,12-epoxyeicosatrienoic
acid (11,12-EET). Eicosanoid extraction and preparation for Ultra
performance liquid chromatography and tandem mass spectrome-
try (UPLC/MS/MS) analysis was conducted according to a previous
report [29]. Quantitative eicosanoid determination was performed
by the stable isotope dilution method [29].
2.8. Fatty acid methylation and GC–MS analysis
Fresh visceral tissue from the amphioxus was homogenized and
subjected to total lipid extraction. The fatty acids were then
methylated for gas chromatograph and mass spectrometry (GC–
MS) analyses [29]. Fatty acid methyl esters were measured using
a Finnigan TRACEGC2000 gas chromatograph equipped with a
TRACE-DSQ detector and fused-silica capillary column (DB-5,
30 m, 0.25 mm ﬁlm thickness, 0.25 mm i.d.; Agilent, CA). The
values are expressed as% total fatty acids, and the total fatty acid
concentration (nmol/g viscera) was calculated by a comparison of
the gas chromatography peak areas relative to that of the C23:0
internal standard [29].3. Results and discussion
3.1. Morphological and pathological characteristics of Chl and
Chl + Amp-treated amphioxus
Amphioxus treated with Chl alone continuously swam errati-
cally and displayed a weakened ability to move. Redness of the
pharynx and gill area was observed in 80% of animals after 4 days
of Chl treatment (Fig. 1A). This regional lesion slowly progressed to
involve the entire body (Fig. 1A). However, amphioxus treated with
Chl + Amp had no visible lesion by day 8 of the trial (Fig. 1A).
Histological sections of Chl-treated amphioxus showed damage
to gill cells of the parallel-sided gill slits at day 4 and necrosis
and loss of gill cells from the primordial bar at day 8. The damageto the epithelial cells of the gill slits increased with time. In con-
trast, only a slight decrease of epithelial cells was found in the
Chl + Amp4d sample, and the loss of gill cells from the primordial
bar in Chl + Amp8d sample was signiﬁcantly less than Chl8d sam-
ple (Fig. 1B). Thus, the combination of Chl and Amp might relieve
the adverse effects of Chl treatment alone in amphioxus.
3.2. Differential digestive tract gene expression by antibiotic
treatments
To understand how antibiotics affect amphioxus homeostasis,
transcriptomic data was obtained to analyze the DEGs after antibi-
otic treatment at day 1 and day 4 according to the morphological
and pathological alterations (Fig. 1). The expression proﬁles of
the samples were remarkably different. Approximately 75% of the
DEGs were down-regulated in the Chl1d sample; approximately
50% were down-regulated in the Chl4d and Chl + Amp1d samples;
and about 25% down-regulation was observed in the Chl + Amp4d
sample (Fig. 2B). Thus, Chl treatment induces the suppression of
gene expression in amphioxus, especially in the Chl1d sample.
Among the 3530 DEGs, approximately 30% were host immune
genes (Fig. 2B and Table S6). The Chl1d sample had the threefold
increased in the number of down-regulated immune genes com-
pared to up-regulation, but the Chl + Amp treatment maintained
a similar ratio of up-regulated to down-regulated genes (Fig. 2B).
Thus, Chl treatment mostly likely induces a severe suppression of
gene expression in the immune system of the amphioxus,
especially in the Chl1d sample, but the status of the immune
system in the Chl + Amp group needs further analysis.
3.3. Antibiotic treatments alter key regulated pathways at the
transcriptomic level
The commonly regulated KEGG pathways between the antibi-
otic treatment groups include some pathways of infection and
stress responses, such as the complement and coagulation cas-
cades, Staphylococcus aureus infection, and autoimmune thyroid
disease (Tables 1 and S3). In addition, pathways related to metabo-
lism, protein digestion and absorption, and cytokine–cytokine
receptor interaction, were also observed as seen in Table 1. Thus,
antibiotic treatment induces complicated physiological and patho-
logical effects in amphioxus. The number of down-regulated genes
in these commonly regulated pathways was higher than the num-
ber of up-regulated genes in both of the antibiotics treatment
groups (Table 1). Although the ratio of the up-regulated genes to
total regulated genes in these pathways did not differ signiﬁcantly
between both antibiotics-treated groups (Table 1), the genes
within the regulated pathways were different and the magnitudes
varied. These differences ultimately contributed to the different
biological effects. Within the uniquely regulated pathways, the
number of down-regulated genes associated the phagosome, anti-
gen processing, and the antigen presentation pathways was higher
than the number of up-regulated genes in the Chl group. On the
contrary, the genes found into be dysregulated in the Chl + Amp
were enriched for pathways related to the signiﬁcant activation
of the arrhythmogenic right ventricular cardiomyopathy (ARVC)
and AA metabolism (Table 1). A previous report indicated that
amphioxus does not possess a proper heart, but has a circulatory
system and a putative hematopoietic tissue domain that is closed
to the dorsal aorta anlages, which is partially linked to the excre-
tory tissues [37]. Thus, it is difﬁcult to link the activation of the
ARVC pathway to physiological changes in the amphioxus because
of the lack of a heart. However, further measurement of the oxy-
genated metabolites produced from AA might provide useful infor-
mation for the investigation of the effects of oxidative stress
following Chl and Chl + Amp treatments.
Fig. 1. The morphological and pathological observation of the antibiotic effects in amphioxus. (A) The morphological changes of the antibiotic treated amphioxus; (B) the
pathological changes of the pharynx and gill of the antibiotic treated amphioxus. (a and b) Amphioxus not treated with antibiotic under 35- and 630 oil. The red square
indicates the parallel-sided gill slits of amphioxus. The deep blue is the gill cell, which is orderly and surrounded at the primordial bar. The arrow indicates the gill cell. (c and
d) Amphioxus exposed to Chl for 4 and 8 days. Scale bar, 50 lm. (e and f) Amphioxus exposed to Chl + Amp for 4 and 8 days. Scale bar, 50 lm. The arrows were used to
compare the tissue damage of the gill slit of the pharynx in the control, Chl-treatment, and Chl + Amp-treatment groups. c: coelom, pb: primordial bar.
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both antibiotic-treatment groups. The genes up-regulated in Chl
group but not in Chl + Amp treatment group were HSP68, a stress
response protein gene, and RTase. The ten genes with the highest
expression found in the Chl + Amp group but not in Chl treatment
were the genes involved in the pathogen recognition and signalpathways, along with the stress protein of hematopoietic prosta-
glandin D synthase (HPGDS), which is involved in prostaglandin
(PGs) production (Tables 2 and S6). Thus, although the
immune-related pathways were to be dysregulated in both of the
antibiotic treatment groups, the genes expression pattern between
the treatment groups was different.
Fig. 2. Distribution, function, and expression pattern of DEGs in the libraries. (A) Distribution of DEGs in the Chl1d, Chl + Amp1d, Chl4d, and Chl + Amp4d libraries from the
transcriptomic data. (B) The percent and number of up- and down-regulated genes of the 3530 DEGs in Chl1d, Chl + Amp1d, Chl4d, and Chl + Amp4d libraries. The red bar
indicates the up-regulated DEGs, and the blue bar indicates the down-regulated DEGs. (C) The enriched GO type of the biological process and the KEGG pathway of the DEGs
appeared in the Chl1d, Chl + Amp1d, Chl4d, and Chl + Amp4d vs. control. ADH: adhesion; EMO: extracellular matrix organization; MP: metabolic process; SAORP: stress and
oxidation–reduction process; ROTS: regulation of inclusion body assembly; MC: molting cycle; RIBA: regulation of inclusion body assembly; MGASD: mammary gland and
sex development; INF: infection; IDAIR: immune disease and immune response; PAP: phagosome and peroxisome; RASP: receptor and signal pathway; SAT: secretion and
transport; MAB: metabolism and biosynthesis; DAA: digestion and absorption; HCl: hematopoietic cell lineage; CMP: cardiomyopathy; NRAR: nucleotide repair and
recombination; DEV: development.
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pathway
A common pathway of the hematopoietic cell lineagewas signif-
icantly down-regulated (FDR < 0.05) in both of the antibiotic treat-
ment groups (Table S3). The main down-regulated cytokines
included CD21, CD22, CD23, CD35, CD42, CD49, TPOs, and Mfhas1
(Fig. 3). The hematopoietic cell lineage can eventually differentiate
into macrophage-like cells and lymphoid cells in mammals. In
mouse, Chl induces the differentiation of activated T cells into lym-
phoblastic leukemia-like cells with expression of CD7, a marker for
immature T cells and T-cell lymphocytic leukemia, thus phenotypi-
cally indicating differentiation toward leukemogenesis [19].
However, whether Chl treatment can inhibit the maturation of the
hematopoietic cells in amphioxus remain elusive. Furthermore,
angiopoietin-related protein like 1 (ANGPTL1) and
angiopoietin-related protein 4 (ANGPT4) of the ﬁbrinogen-related
proteins were up-regulated in the Chl + Amp treatment group but
down-regulated in Chl treatment (Table 2). This might mean that,
to some extent, a different status of the immune system is induced
in each of the antibiotic treatment groups.
3.5. Immunomodulation in the Chl alone and Chl + Amp treatment
groups
Another common pathways dysregulated in both of the
antibiotic treatment groups include the immune-related pathway
of bacterial infections and the complement and coagulation cas-
cades. The amphioxus immune system possesses a microorganism
recognition system with expanded gene numbers and diversedomain architecture of PRR families, cytokines and signal trans-
ducers, and effectors. The microbe-associated molecular patterns
(MAMPs) genes, including scavenger receptor cysteine-rich
protein (SRCR), leucine-rich repeat-containing protein (LRR), and
ﬁbrinogen-related proteins, had a higher level of gene expression
in the Chl + Amp group compared with the Chl group (Fig. 3).
TLR2 was also increased in the Chl + Amp group, but
down-regulated in Chl4d sample (Fig. 3). The potential
Gram-positive bacteria receptors for the peptidoglycan recognition
protein, chitin-binding protein, lysozyme, C-type lectin (CTL), and
ﬁcolin in the PRR families were down-regulated in both groups
(Fig. 3). Further examination revealed that the expression of genes
in the PRR families in the Chl + Amp treatment group was higher
than Chl treatment group when assessing the ratio of
Chl + Amp1d/Chl1d and Chl + Amp4d/Chl4d (Fig. 3). Thus,
Chl + Amp treatment might relieve the effects of immune suppres-
sion in the PRR families in amphioxus treated with Chl alone.
As for signal transducers and effectors, MyD88 and IjB were
up-regulated expression in both of the antibiotic treatment groups
at day 4. TRAF3 and RIPK1 were signiﬁcantly up-regulated in
Chl + Amp4d sample. A majority of the NF-jB target genes, includ-
ing NLR, TNFR, TNF, and various cytokines, were signiﬁcantly
induced in the Chl + Amp treatment group, but not with Chl treat-
ment alone (Fig. S2). The expression dynamics analysis indicated
that the lectin pathway and C1q-like pathway were activated in
the mucosal immune responses of the digestive tract (Fig. S1).
The expression of MACPF genes and the typical immune genes of
the SOUL heme-binding protein (a regulatory factor in innate
immune response) were increased in the Chl + Amp group but
not in the Chl group (Fig. S1). The expression of the acute phase
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620 D. Yuan et al. / FEBS Open Bio 5 (2015) 615–624protein defensin was increased with both antibiotic treatments. A
severe reduction of mucus was observed at day 4 in the Chl group
but not in the Chl + Amp group (Table S6). In a more detailed com-
parison, the gene expression of the signal transducers and effec-
tors in the Chl + Amp-treatment group was higher than the
Chl-treatment group when the ratios of Chl + Amp1d/Chl1d and
Chl + Amp4d/Chl4d were examined (Fig. 3). Thus, Chl treatment
induces suppression of the PRR families and the signal transduc-
ers and effectors in amphioxus. In contrast, Chl + Amp treatment
results in immune stimulation to some extent via KEGG cluster-
ing. These ﬁndings suggest that Amp might help to relieve
immune suppression in amphioxus caused by Chl treatment.
3.6. Antibiotic treatment results in altered eicosanoid production
A uniquely regulated AA metabolism pathway was activated in
Chl + Amp group but not in Chl group, indicating one of the
marked features of both of the antibiotic treatments (Table 1).
As for the gene expression of the enzymes in AA metabolism,
amphioxus LOX-1 mRNA was strongly expressed in the pharynx
and gill, hepatic cecum, gonad, and intestine [29]. Amphioxus
has two homologous COXs, named COX-c and COX-d [38].
Amphioxus COX-c/d mRNAwas strongly expressed in the pharynx
and gill, hepatic cecum, mature gonad, and intestine as shown by
in situ hybridization (Fig. 4). The metabolites and mediators from
AA through the COX, LOX, and CYP pathways in the amphioxus
muscle and digestive tract were quantiﬁed. The eicosanoid con-
centration in muscle was found to be only about 5% of that in
the digestive tract. Moreover, the levels of PGE2, 12-HHTrE, and
9-HETE in muscle were lower than the detection limit
(Table S7). Thus, the pharynx gill slits and the intestine are the
major locations for gene expression of amphioxus COX and
LOX-1, and eicosanoids production from AA.
The genes of phospholipase A2 (PLA2), HPGDS, and CYP2J2,
which are involved in the eicosanoids production, were signiﬁ-
cantly up-regulated in the Chl + Amp group (Fig. S2 and
Table S6). The Chl + Amp1d sample showed the highest level of
eicosanoids production from AA through the COX, LOX, and CYP
pathways, whereas the Chl + Amp4d sample returned to the con-
trol levels (Fig. 5). The percentage of eicosanoids from AA through
the COX, LOX, and CYP pathways in the amphioxus digestive tract
reached 3%, 80%, and 17%, respectively. In detail, the high
increased level of eicosanoids in Chl + Amp1d sample was from
8-, 12-HETEs from the LOX pathway and 14(15)-EET from the
CYP pathway, while PGD2 and PGE2 from the COX pathway
showed a relatively low increase (Fig. 5 and Table S8). In the
Chl + Amp1d sample, PGD2 and PGE2 from the COX pathway had
a 1.4-fold increase compared to control; and 8-, 12-HETEs from
the LOX pathway and 14(15)-EET from the CYP pathway had a
1.6-fold and 2.1-fold increase, respectively. The lipid mediators
from the COX and LOX pathways returned to the control levels
in the Chl + Amp4d sample; but the lipid mediators from the
CYP pathway showed a 1.3-fold decrease compared to the control
level (Fig. 5 and Table S8). Eicosanoids from the COX, LOX, and
CYP pathways showed a 2.3-, 2.2-, and 1.7-fold decrease in the
Chl1d sample and a 1.8-, 3.2-, and 2.4-fold decrease in the
Chl4d sample, respectively (Fig. 5 and Table S8). The substrate
of AA was signiﬁcantly increased in the Chl-treatment groups
and decreased in the Chl + Amp-treatment group (Fig. 5D). Thus,
the dynamic changes of AA and eicosanoid levels indicated that
the inhibition of AA metabolism resulted in a decrease of eicosa-
noids from AA and AA accumulation in the Chl-treatment group;
the activation of AA metabolism induced an increase of eicosa-
noids from AA and AA consumption in the Chl-treatment group.
Oxygenated metabolites of AA play a central role in immune
responses through the recruitment and activation of neutrophil
Fig. 3. Expression patterns of DEGs in amphioxus after Chl and Chl + Amp treatments. TPO: thrombopoietin; Mfhas1: malignant ﬁbrous histiocytoma ampliﬁed sequence 1;
LOX: lipoxygenase; HPGDS: hematopoietic prostaglandin D synthase; CYP2J2: cytochrome P450 2J2; EPHX1: epoxide hydrolase 1; TLR: toll-like receptor; NLR: NOD-like
receptor; LRR: leucine-rich repeat-containing protein; PGRP: peptidoglycan recognition protein; CBP: chitin binding protein; CTL: C-type lectin; SRCR: scavenger receptor
cysteine-rich protein; C1q: complement C1q protein; Apaf1: apoptotic peptidase activating factor 1; BIR: baculoviral IAP repeat-containing protein; PDCD: programmed cell
death; CytC: cytochrome C; BCL: B-cell lymphoma; NAIP: neuronal apoptosis inhibitory protein; DAPK: death-associated protein kinase; IL-17: Interleukin-17; TIR-adaptor:
Toll-interleukin receptor adaptor; CCP: complement control protein; TNF: tumor necrosis factor; TNFR: tumor necrosis factor receptor; TRAF: TNF receptor-associated factor;
TRAIP: TRAF-interacting protein; RIPK: receptor (TNFRSF)-interacting serine–threonine kinase; MyD88: myeloid differentiation primary response protein; NFKBIL1: NF-
kappa-B inhibitor-like protein 1; IKBK: I-kappaB kinase; TF: transcription factor; C2: complement component 2; MACPF: membrane attack complex component/perforin;
SHB: SOUL haem binding protein. The detailed gene expression of the putative complement and coagulation cascade and TLR signaling pathway is shown in Figs. S1 and S2.
The detailed digits are shown in Table S6.
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of bioactive lipid level can induce a series of diseases, such as
chronic inﬂammation, diabetes, cancer, and cardiovascular disease
[40]. In invertebrates, eicosanoids also play important roles at the
cellular immune defenses and mediate certain host–parasite and
predator–prey interactions [41–43]. Some enzymes for eicosanoid
production may be involved in the regulation of the dinoﬂagellatesymbiosis with corals [44]. The high level of PGs might be regarded
as chemical defense in the struggle between predators and prey
[45–47]. Furthermore, eicosanoids are mainly distributed in the
amphioxus digestive tract, which is also the main locus of the dis-
tribution of phagocytes and lymphocyte-like cells and the occur-
rence of immune responses [28,48]. However, whether
eicosanoids participate in the amphioxus immune response and
Table 2
Genes were highly up-regulated in the digestive tract of amphioxus with Chl/Chl + Amp treatment. Time course fold-change of the differential expression of the 10 most frequent
genes (FDA < 0.05). Color-scale: 7 (dark-blue) – 1 (white) 1–7 (dark-red) [linear].
Note:
Fig. 4. Section in situ hybridization analysis of BbtCOX-c and BbtCOX-d. Positive hybridization signal is shown in deep blue. (A) Section in situ hybridization analysis of
BbtCOX-c with sense probe; (B and C) BbtCOX-c with anti-sense probe; positive hybridization signal is strongly expressed in the pharynx and gill, cecum, gonad, and
intestine. (D) Section in situ hybridization analysis of BbtCOX-d with sense probe; (E and F) BbtCOX-d with anti-sense probe; positive hybridization signal is strongly
expressed in the pharynx and gill, cecum, gonad, and intestine. n = notochord, i = intestine, g = gonad, p = pharynx and gill, c = cecum, e = endostyle. Scale bar = 500 lm.
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Fig. 5. Dynamic changes of the level of AA and eicosanoids from AA in amphioxus with antibiotics treatments. *Chl1d, Chl4d, Chl + Amp1d, Chl + Amp4d compared to control,
respectively (t-test, P < 0.05); #Chl treatment compared to Chl + Amp treatment (ANOVA and post tests, P < 0.05).
D. Yuan et al. / FEBS Open Bio 5 (2015) 615–624 623whether the dynamic eicosanoid level reﬂects the immune status
requires further investigation.
4. Conclusion
In summary, the present study indicates that Chl treatment
induces immune suppression in amphioxus. The addition of Amp
might relieve the suppression effects induced Chl in the amphioxus
immune system. Furthermore, oxygenated metabolites of AA are
the crucial signals that reﬂect the effect of Chl on amphioxus.
These results exploring the effects of Chl and Chl + Amp treatment
on AA metabolism in amphioxus describes a previously unknown
pathogenesis that has been reported as an adversarial effect asso-
ciated with Chl therapy in aquatic animals.
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